EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Society for Maternal‐Fetal Medicine Consult Series #75: Evaluation and management of non‐immune hydrops fetalis

Society for Maternal‐Fetal Medicine (SMFM), Teresa N Sparks iD, Mary E Norton iD, SMFM Publications Committee

Pregnancy · 2026-03 · 2 (2)

DOI: 10.1002/pmf2.70208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pregnancy, online erschienen am 06.03.2026. Verfasst von Society for Maternal‐Fetal Medicine (SMFM) und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐immune hydrops fetalis (NIHF) can result from a multitude of underlying causes, such as fetal genetic diseases, congenital anomalies, infections, fetal arrhythmias, placental tumors, monochorionic twin complications, and other disorders. Management is complex and rooted in the preferences of the pregnant individual and the known or suspected etiology of NIHF. In this Consult, we review general considerations and a contemporary approach to the diagnosis, evaluation, and management of NIHF, providing recommendations based on the available evidence. The following are the Society for Maternal‐Fetal Medicine's recommendations: (1) we recommend fetal diagnostic testing for all pregnancies when one or more fetal effusions are detected; this testing should include chromosomal microarray analysis (CMA) with or without karyotype. When infectious etiologies are in the differential diagnosis, polymerase chain reaction studies should also be performed (grading of recommendations assessment, development, and evaluation [GRADE] 1C); (2) we recommend that exome or genome sequencing be offered in pregnancies with NIHF or NIHF spectrum following CMA or karyotype that does not yield a diagnosis and in the absence of another suspected etiology. If the risk of aneuploidy is low or a single‐gene disorder is strongly suspected, offering exome or genome sequencing concurrently with CMA is reasonable (GRADE 1C); (3) we recommend that all patients who develop mirror syndrome in the setting of NIHF receive individualized counseling about delivery or abortion care; expectant management should be reserved only for rare circumstances, after counseling about the maternal risks and shared decision‐making (GRADE 1C); (4) given the associated maternal risks, we recommend that all patients with pregnancies complicated by NIHF receive individualized counseling and be offered all management options, including abortion care (GRADE 1C); (5) we recommend that timing of delivery be individualized for each pregnancy with NIHF and that preterm delivery be reserved for obstetrical indications such as preeclampsia or mirror syndrome, preterm labor or premature rupture of membranes, new or worsening NIHF, or when the overall maternal or fetal risks of continued management are expected to outweigh those of delivery (GRADE 1C); (6) we recommend antenatal corticosteroids for continuing pregnancies with NIHF when preterm delivery is anticipated within 7 days, if neonatal resuscitation is desired and would be offered (GRADE 1C); (7) we recommend that cesarean delivery be performed for standard obstetrical indications in the setting of NIHF when postnatal resuscitation and life‐supporting care are planned for the neonate (GRADE 1C). This Consult replaces Society for Maternal‐Fetal Medicine Clinical Guideline #7: Non‐immune hydrops fetalis.

Schlagwörter

Stichwörter der Autor:innen

congenital anomalycongenital infectionfetal effusiongenetic diseasehydrops fetalismirror syndromenon‐immune hydrops fetalisnon‐immune hydrops fetalis spectrumpreterm birthultrasound

Autor:innen und Institutionen

ORCID-Profile: Teresa N Sparks, Mary E Norton

Zitieren

APA

Society for Maternal‐Fetal Medicine (SMFM), Sparks, T. N., Norton, M. E., & SMFM Publications Committee (2026). Society for Maternal‐Fetal Medicine Consult Series #75: Evaluation and management of non‐immune hydrops fetalis. Pregnancy, 2(2). https://doi.org/10.1002/pmf2.70208

Vancouver

Society for Maternal‐Fetal Medicine (SMFM), Sparks TN, Norton ME, SMFM Publications Committee. Society for Maternal‐Fetal Medicine Consult Series #75: Evaluation and management of non‐immune hydrops fetalis. Pregnancy. 2026;2(2). doi:10.1002/pmf2.70208

BibTeX
@article{SocietyforMaternalFetalMedicineSMFM2026,
  author = {Society for Maternal‐Fetal Medicine (SMFM), Society for Maternal‐Fetal Medicine (SMFM) and Sparks, Teresa N and Norton, Mary E and SMFM Publications Committee, SMFM Publications Committee},
  title = {Society for Maternal‐Fetal Medicine Consult Series #75: Evaluation and management of non‐immune hydrops fetalis},
  journal = {Pregnancy},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.1002/pmf2.70208}
}
Kostenlos starten →